|
IQVIA™ Real-World Insights Bibliography
| Empagliflozin is Associated with Lower Risk of Cardiovascular Events and All-Cause Mortality in Routine Care in East Asia: Results from the EMPRISE Study
|
| Author(s): Dae Jung Kim (1), Wayne H-H Sheu (2), Wook-Jin Chung (3), Daisuke Yabe (4-7), Kyoung Hwa Ha (1), Masaomi Nangaku (8), Elise Chia-Hui Tan (9), Koichi Node (10), Atsutaka Yasui (11), Weiyu Lei (12), Sunwoo Lee (13), Laura Saarelainen (14), Anouk Deruaz-Luyet (15), Moe H. Kyaw (16) and Yutaka Seino (4,17), EMPRISE East Asia Study Group
|
| Affiliations(s): "1
Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, South Korea
2
Division of Endocrinology and Metabolism, Taipei Veterans General Hospital, Taipei, Taiwan
3
Department of Cardiovascular Medicine, Gachon University Gil Medical Center, Incheon, South Korea
4
Kansai Electric Power Medical Research Institute, Kobe, Japan
5
Department of Diabetes, Metabolism and Endocrinology/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan
6
Center for Healthcare Information Technology, Tokai National Higher Education and Research System, Nagoya, Japan
7
Division of Metabolism and Molecular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
8
Division of Nephrology and Endocrinology, The University of Tokyo, Tokyo, Japan
9
National Research Institute of Chinese Medicine, Ministry of Health and Welfare, Taipei, Taiwan, and Institute of Hospital and Healthcare Administration, National Yang-Ming University, Taipei, Taiwan
10
Department of Cardiovascular Medicine, Saga University, Saga, Japan
11
Nippon Boehringer Ingelheim Co. Ltd., Tokyo, Japan
12
Boehringer Ingelheim Taiwan Ltd., Taipei, Taiwan
13
Boehringer Ingelheim Korea Ltd, Seoul, Korea
14
IQVIA, Espoo, Finland
15
Boehringer Ingelheim International GmbH, Ingelheim, Germany
16
Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA
17
Kansai Electric Power Hospital, Osaka, Japan
" |
Publication(s): "JDI journal
Virtual Conference: ACC, May 2021"
|
| Document Type(s): Article, |
| Countries: Japan, Korea, Taiwan, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease, Diabetes, Drug safety, Drug Utlization Study,
2023 |
|
L:
A: |
English
Clinical setting: hospital, Clinical setting: Primary care, Retrospective cohort analysis, |
|
 |
| |
| |
| Effectiveness and safety of empagliflozin in routine care in Europe and East Asia: results from
the empagliflozin comparative effectiveness and safety (EMPRISE) study
|
| Author(s): A. Karasik1
, S. Lanzinger2
, E. Chia-Hui Tan3
, D. Yabe4
, D. Jung Kim5
, W. H-H Sheu6
, C. MelzerCohen1
, R.W. Holl2
, K. Ha5
, T. Nyström7
, L. Niskanen8
, M. Linnemann Jensen9
, M.H. Kyaw10, J.
Núñez11, EMPRISE EU and East Asia Study Group; |
| Affiliations(s): Maccabi Research & Innovation Center, Tel Aviv University, Tel Aviv, Israel, 2
Inst. for
Epidemiology & Medical Biometry, Uni. of Ulm, Ulm, Germany, 3National Research Inst. of Chinese
Medicine, Taipei, Taiwan, 4Dept. of Diabetes and Endocrinology, Gifu University Graduate School of
Medicine, Gifu, Japan, 5Dept. of Endocrinology & Metabolism, Ajou Uni. School of Medicine,
Suwon, Republic of Korea, 6Taipei Veterans General Hospital, Taipei, Taiwan, 7Dept. of Clinical
Science & Education, Södersjukhuset, Karolinska Institutet, Solna, Sweden, 8Department of Medicine,
Päijät-Häme Central Hospital, Lahti, Finland, 9
IQVIA, Copenhagen, Denmark, 10Boehringer
Ingelheim Pharmaceutical Inc., Ridgefield, USA, 11Dept. of Cardiology, Hospital Clínico
Universitario de Valencia, Valencia, Spain |
Publication(s):
https://doi.org/10.2337/DB21-127-LB
Virtual EASD 2021, 57 Annual Meeting, 27 September - 10 October 2021
|
| Document Type(s): Abstract, |
| Countries: Finland, Germany, Israel, Japan, South Korea, Spain, Sweden, Taiwan, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease, Diabetes,
2021 |
|
L:
A: |
English
Database Study, Methodology, Population Based Study, |
|
|
| |
| |
| Cardiovascular Effectiveness of Empagliflozin Compared to DPP-4i in Routine Care in East Asia: Results from the EMPRISE study |
| Author(s): Dae Jung Kim, Wayne H.-H. Sheu, Wook-Jin Chung, Daisuke Yabe, Kyoung Hwa Ha, Elise Chia-Hui Tan, Yusuke Taneda, Vanessa Lei, Laura Saarelainen, Anouk Deruaz-Luyet, Moe H. Kyaw, Yutaka Seino, EMPRISE East Asia Study Group, Boehringer Ingelheim International GmbH, Ingelheim, Germany, StatFinn - EPID Research an IQVIA Company, Espoo, Finland |
| Affiliations(s): 1 Ajou University, Suwon, South Korea; 2 Taichung Veterans General Hospital, Taichung, Taiwan; 3 Gachon University Gil Medical Center, Incheon, South Korea; 4 Kansai Electric Power Medical Research Institute, Kobe, Japan; 5 Gifu University Graduate School of Medicine, Gifu, Japan; 6 National Research Institute of Chinese Medicine, Taipei, Taiwan; 7 Nippon Boehringer Ingelheim Co. Ltd., Tokyo, Japan; 8 Boehringer Ingelheim Taiwan Ltd., Taipei, Taiwan; 9 IQVIA, Espoo, Finland; 10 Boehringer Ingelheim International GmbH, Ingelheim, Germany; 11 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA; 12 Kansai Electric Power Hospital, Osaka, Japan |
Publication(s): J Am Coll Cardiol. 2021 May, 77 (18_Supplement_1) 542.
https://doi.org/10.1016/S0735-1097(21)01901-X
|
| Document Type(s): Abstract, Presentation, |
| Countries: Japan, South Korea, Taiwan, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease, Diabetes,
2021 |
|
L:
A: |
English
Database Study, Methodology, Observational study, |
|
|
| |
| |
| Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study |
| Author(s): Yutaka Seino*, Dae Jung Kim, Daisuke Yabe, Elise Chia-Hui Tan, Wook-Jin Chung, Kyoung Hwa Ha, Masaomi Nangaku, Koichi Node, Riho Klement**, Atsutaka Yasui, Wei-Yu, Sunwoo Lee, Moe H Kyaw, Anouk Deruaz-Luyet, Kimberly G Brodovicz,Wayne H-H Sheu, on behalf of the EMPRISE East Asia study group |
| Affiliations(s): * Kansai Electric Power Medical Research Institute, Kobe, Japan and Kansai Electric Power Hospital, Osaka, Japan **EPID Research an IQVIA company, Tartu, Estonia |
Publication(s): Endocrinology, Diabetes and Metabolism 2020;00:e00183
|
| Document Type(s): Article, |
| Countries: Japan, South Korea, Taiwan, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease, Diabetes,
2020 |
|
L:
A: |
English
Epidemiological study, Retrospective database analysis, |
|
|
| |
| |
| Clinical characteristics of Glioblastoma Multiforme (GBM) Patients Who Reached 400 Days Post Diagnostic from a Retrospective Real-World Data |
| Author(s): Mitrofan L.M.1,Krukas-Hampel M.R.2, Mendoza L.A.3 |
| Affiliations(s): 1 IQVIA, Paris, FR; 2IQVIA New York, US; 3IQVIA, Prague, CZ |
Publication(s): ESMO 2018
|
| Document Type(s): Poster, |
| Countries: Australia, Brazil, Canada, France, Germany, Italy, Mexico, Spain, Taiwan, UK, |
C:
Y: |
Oncology,
2018 |
|
L:
A: |
English
|
|
|
| |
| |
| Clinical Characteristics of 3,030 Glioblastoma Multiforme (GBM) Patients in High, Upper Middle and Lower Middle Economic Regions Based on Real-World Data (RWD) |
| Author(s): Mitrofan L1 , M.R. Krukas-Hampel M.R2 , L.A. Mendoza L.A3 |
| Affiliations(s): IQVIA, Paris, FR; IQVIA New York, US; IQVIA, Prague, CZ |
Publication(s): ESMO 2018
|
| Document Type(s): Poster, |
| Countries: Australia, Brazil, Canada, France, Germany, Italy, Mexico, Spain, Taiwan, UK, |
C:
Y: |
Oncology,
2018 |
|
L:
A: |
English
|
|
|
| |
| |
| The Medication Adherence in Schizophrenia Management by Using Second Generation Antipsychotics in Taiwan: A Population Study Based on Nhrid |
| Author(s): Chung C1,Tai TA2,Chou KP2 |
| Affiliations(s): 1-Mackay Medical College , New Taipei City , Taiwan
2-IMS Health Taiwan , Taipei , Taiwan |
Publication(s): Value Health. 2016 nov; 19(7): A842
|
| Document Type(s): Abstract, |
| Countries: Taiwan, |
| Click here for the abstract |
C:
Y: |
Mental health,
2016 |
|
L:
A: |
English
Retrospective database analysis, |
|
|
| |
| |
| Afatinib in the treatment of EGFR mutation-positive NSCLC - A network meta-analysis. |
| Author(s): Popat S1, Mok T2, Yang JC3, Wu YL4, Lungershausen J5, Stammberger U5, Griebsch I5, Fonseca T6, Paz-Ares L7 |
| Affiliations(s): 1Royal Marsden Hospital, London, UK. 2State Key Laboratory of Southern China, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong.
3National Taiwan University, Taipei, Taiwan.
4Guangdong Lung Cancer Institute, Guangzhou, China.
5Boehringer Ingelheim GmbH, Ingelheim, Germany.
6IMS Health, London, UK.
7Instituto de Biomedicina de Sevilla - IBIS (University Hospital Virgen del Rocío, US, CSIC), Seville, Spain.
|
Publication(s): Lung Cancer. 2014 Aug;85(2):230-8
|
| Document Type(s): Article, |
| Countries: China, Germany, Hong Kong, Spain, Taiwan, UK, |
| Click here for the abstract |
C:
Y: |
Oncology,
2014 |
|
L:
A: |
English
Meta analysis, |
|
|
| |
| |
| Evolution of oral anticancer treatments use in France from 2004 to 2012: the Re-ACTOR Study. |
| Author(s): Benjamin L, Maurel F, Bardoulat I, Ricarte C |
| Affiliations(s): 1 Glaxosmithkline, 2 Health Economics and Outcomes Research, Marly le Rol, France, 3 IMS Health, La Defense, France |
Publication(s): ISPOR Europe 2013 Annual meeting
|
| Document Type(s): Poster, |
| Countries: China, France, Germany, Italy, Japan, Korea, Spain, Taiwan, UK, |
| Click here for the abstract |
C:
Y: |
Oncology,
2013 |
|
L:
A: |
English
Retrospective database analysis, |
|
|
| |
| |
| Current situation of oral anticancer treatments use in France: the ACTOR Study. |
| Author(s): Benjamin L, Maurel F, Bardoulat I, Ricarte C |
| Affiliations(s): 1 Glaxosmithkline, 2 Health Economics and Outcomes Research, Marly le Rol, France, 3 IMS Health, La Defense, France |
Publication(s): ISPOR Europe 2013 Annual meeting
|
| Document Type(s): Abstract, |
| Countries: China, France, Germany, Italy, Japan, Korea, Spain, Taiwan, UK, |
| Click here for the abstract |
C:
Y: |
Oncology,
2013 |
|
L:
A: |
English
|
|
|
| |
| |
 1 of 2 
|
|
